Paradigm Pharmaceuticals, LLC

Roseville, MN 55113

SBIR Award Summary

Total Number of Awards 22
Total Value of Awards $3.68MM
First Award Date 01/01/02
Most Recent Award Date 04/01/07

Key Personnel

Last Name Name Awards Contact
Venkatachalam Taracad Venkatachalam 3
Waurzyniak Barbara Waurzyniak 1
D'Cruz Osmond J D'Cruz 11
Mahajan Sandeep Mahajan 2
Cetkovic-Cvrlje Marina Cetkovic-Cvrlje 1
Vassilev Alexei Vassilev 2
Samuel Peter Samuel 1
Dumez Darin Dumez 1

22 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/07 - 03/31/08

DESCRIPTION (provided by applicant): There is an urgent need, worldwide, for improved contraceptives, especially prophylactic contraceptives. Barrier methods are the only class of contraceptives that protects users against sexually transmitted diseases. However, currently available spermicidal contraceptives suffer from poor efficacy and/or have...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/15/06 - 03/31/07

DESCRIPTION (provided by applicant): There is an urgent need, worldwide, for improved contraceptives, especially prophylactic contraceptives. Barrier methods are the only class of contraceptives that protects users against sexually transmitted diseases. However, currently available spermicidal contraceptives suffer from poor efficacy and/or have...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/05 - 08/31/06

DESCRIPTION (provided by applicant): The emergence of AIDS as a disease spread through sexual intercourse has prompted the search for new, effective, safe, and female-controlled vaginal microbicides for curbing mucosal viral transmission. Microbicides that are currently being investigated are directed mainly at preventing pregnancy as well as pr...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/05 - 08/31/07

DESCRIPTION (provided by applicant): The current pandemic of sexually transmitted HIV/AIDS has created an urgent need for a new type of microbicide: one that is both a spermicide and a virucide. The goal of the proposed Phase II work is to further develop WHI-07, a novel 5-bromo 6-methoxy aryl phosphoramidate derivative of 3'-azido-3'-deoxythymi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/15/05 - 02/28/06

DESCRIPTION (provided by applicant): Human immunodeficiency virus (HIV) -1 the etiologic agent of AIDS is the fastest growing cause of death in men and women of reproductive age. In the absence of effective treatment as well as anti-HIV therapy or vaccine, new emphasis has been placed on the development of anti-HIV agents capable of reducing thi...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/01/05 - 03/31/07

DESCRIPTION (provided by applicant): We have rationally designed the leflunomide metabolite analog alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)-propenamide (LFM-A13) as a specific inhibitor of the protein tyrosine kinase, Bruton's tyrosine kinase (BTK). LFM-A13 is a chemosensitizing anti-leukemic agent with anti-thrombotic properti...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/27/04 - 08/31/05

DESCRIPTION (provided by applicant): The current pandemic of sexually transmitted HIV/AIDS has created an urgent need for a new type of microbicide: one that is both a spermicide and a virucide. The goal of the proposed Phase II work is to further develop WHI-07, a novel 5-bromo 6-methoxy aryl phosphoramidate derivative of 3'-azido-3'-deoxythymi...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 01/01/04 - 12/31/04

DESCRIPTION (provided by applicant): We have rationally designed the leflunomide metabolite analog alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl)-propenamide (LFM-A13) as a specific inhibitor of the protein tyrosine kinase, Bruton's tyrosine kinase (BTK). LFM-A13 is a chemosensitizing anti-leukemic agent with anti-thrombotic properti...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/29/03 - 09/30/04

DESCRIPTION (provided by applicant): The rationally designed Janus kinase 3 (JAK3) inhibitor 4-(3',5'-dibromo-4'-hydroxyphenyl)- anmino-6,7-dirnethoxyquinazoline (WHI-P97) exhibits potent in vivo biologic activity in a mouse model of allergic asthma at nontoxic dose levels. Further development of WHI-P97 may therefore provide the basis for new ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/28/03 - 08/31/04

DESCRIPTION (provided by applicant): The emergence of AIDS as a disease spread through sexual intercourse has prompted the search for new, effective, safe, and female-controlled vaginal microbicides for curbing mucosal viral transmission. Microbicides would provide protection by inactivating viruses or preventing viruses from replicating either...

Load More